Abstract:Aim: Leflunomide is an immunosuppressive agent marketed as a disease-modifying antirheumatic drug. But it causes severe side effects, including fatal hepatitis and liver failure. In this study we investigated the contributions of hepatic metabolism and transport of leflunomide and its major metabolite teriflunomide to leflunomide induced hepatotoxicity in vitro and in vivo . Methods: The metabolism and toxicity of leflunomide and teriflunomide were evaluated in primary rat hepatocytes in vitro . Hepatic cytochrome P450 reductase null ( HRN ) mice were used to examine the PK profiling and hepatotoxicity of leflunomide in vivo . The expression and function of sodium/bile acid cotransporter (NTCP) were assessed in rat and human hepatocytes and NTCP-transfected HEK293 cells. After Male Sprague-Dawley (SD) rats were administered teriflunomide (1,6, 12 mg·kg −1 ·d −1 , ig) for 4 weeks, their blood samples were analyzed. Results: A nonspecific CYPs inhibitor aminobenzotriazole (ABT, 1 mmol/L) decreased the IC 50 value of leflunomide in rat hepatocytes from 409 to 216 μmol/L, whereas another nonspecific CYPs inhibitor proadifen (SKF, 30 μmol/L) increased the cellular accumulation of leflunomide to 3.68-fold at 4 h. After oral dosing (15 mg/kg), the plasma exposure (AUC 0-t ) of leflunomide increased to 3-fold in HRN mice compared with wild type mice. Administration of leflunomide (25 mg·kg −1 ·d −1 ) for 7 d significantly increased serum ALT and AST levels in HRN mice; when the dose was increased to 50 mg·kg −1 ·d −1 , all HRN mice died on d 6. Teriflunomide significantly decreased the expression of NTCP in human hepatocytes, as well as the function of NTCP in rat hepatocytes and NTCP-transfected HEK293 cells. Four-week administration of teriflunomide significantly increased serum total bilirubin and direct bilirubin levels in female rats, but not in male rats. Conclusion: Hepatic CYPs play a critical role in detoxification process of leflunomide, whereas the major metabolite teriflunomide suppresses the expression and function of NTCP, leading to potential cholestasis.

Leflunomide nanocarriers: a new prospect of therapeutic applications

Inhibition of canonical WNT/β-catenin signaling is involved in leflunomide (LEF)-mediated cytotoxic effects on renal carcinoma cells.

Chitosan coated clove oil-based nanoemulsion: An attractive option for oral delivery of leflunomide in rheumatoid arthritis

Mitochondrial Dysfunction Induced by Leflunomide and Its Active Metabolite.

Antirheumatic drug leflunomide attenuates atherosclerosis by regulating lipid metabolism and endothelial dysfunction via DHODH/AMPK signaling pathway

Lipid-based nanocarriers: an attractive approach for rheumatoid arthritis management

Leflunomide, a New Disease-Modifying Drug for Treating Active Rheumatoid Arthritis in Methotrexate-Controlled Phase II Clinical Trial.

Dual Drug Nanoparticle Synergistically Induced Apoptosis, Suppressed Inflammation and Protected Autophagic Response in Rheumatoid Arthritis Fibroblast-like Synoviocytes

Evidence-based Treatment of a Patient with Rheumatoid Arthritis with Leflunomide

Inhibition of Hepatic Cytochrome P450 Enzymes and Sodium/bile Acid Cotransporter Exacerbates Leflunomide-Induced Hepatotoxicity.

Advancements in rheumatoid arthritis therapy: a journey from conventional therapy to precision medicine via nanoparticles targeting immune cells

Therapeutic Potential of Nanocarriers in the Management of Rheumatoid Arthritis

Treatment of Proliferative Lupus Nephritis with Leflunomide and Steroid: a Prospective Multi-Center Controlled Clinical Trial

Surface-decorated nanoliposomal leonurine targets activated fibroblast-like synoviocytes for efficient rheumatoid arthritis therapy

[Effects of Leflunomide and Its Active Metabolite on the Production and Mrna Expression of TNF-alpha in Peritoneal Macrophages and Synovial Cells with Adjuvant Arthritis in Rats].

Integrating Nanotechnological Advancements of Disease-Modifying Anti-Rheumatic Drugs into Rheumatoid Arthritis Management

Systematic Review on Leflunomide Treating Refractory Nephrotic Syndrome

Towards understanding the role of nanomedicine in targeting TNFR2 in rheumatoid arthritis

Leflunomide Increases Hepatic Exposure to Methotrexate and Its Metabolite by Differentially Regulating Multidrug Resistance–Associated Protein Mrp2/3/4 Transporters via Peroxisome Proliferator–Activated Receptor α Activation

Emerging Approaches for the Treatment of Rheumatoid Arthritis: An Outlook

Endoplasmic Reticulum Stress and MAPK Signaling Pathway Activation Underlie Leflunomide-Induced Toxicity in HepG2 Cells.